The findings suggest that "supportive care and management of geriatric vulnerabilities at baseline may improve outcomes and ...

Baseline geriatric vulnerabilities and QOL scores are associated with survival after chemotherapy in older adults with metastatic pancreatic cancer, researchers found.

Biomarker testing is often used to help connect a patient with the right treatment at the right time. After a cancer ...

The data revealed that the use of the Trans-Arterial Micro-Perfusion (TAMP) device resulted in greater drug potency and fewer ...

Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

This breakthrough represents a beacon of hope in the fight against pancreatic cancer and other hard-to-treat malignancies.

ImmunoMet Therapeutics, Inc., ("ImmunoMet", or the "Company"), a clinical stage biotechnology company committed to giving ...

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

The new findings show the cancer mortality rate declined by 34% from 1991 to 2022 in the United States, averting ... Experimental Blood Test for Pancreatic Cancer Undergoing Clinical Development ...

SIL-204 administered in an extended release formulation reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis, in human pancreatic tumors harboring a G12D mutation ...

Ajay Goel, PhD, AGAF, discusses how the development and validation of novel non-invasive biomarkers can improve early detection and ultimately impact patient outcomes for patients.